WallStSmart

Merck & Company Inc (MRK)vsPhreesia Inc (PHR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 13171% more annual revenue ($65.77B vs $495.59M). MRK leads profitability with a 13.6% profit margin vs 1.9%. MRK trades at a lower P/E of 32.4x. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

PHR

Hold

44

out of 100

Grade: D

Growth: 6.0Profit: 4.5Value: 5.7Quality: 5.5
Piotroski: 3/9Altman Z: -0.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-40.6%)

Margin of Safety

-40.6%

Fair Value

$80.96

Current Price

$128.66

$47.70 premium

UndervaluedFair: $80.96Overvalued
PHRUndervalued (+72.6%)

Margin of Safety

+72.6%

Fair Value

$45.65

Current Price

$9.13

$36.52 discount

UndervaluedFair: $45.65Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$283.78B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

PHR2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.269/10

Conservative balance sheet, low leverage

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.4x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PHR4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$622.45M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
2.6%3/10

ROE of 2.6% — below average capital efficiency

Profit MarginProfitability
1.9%3/10

1.9% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : PHR

The strongest argument for PHR centers on Debt/Equity, Price/Book. Revenue growth of 12.9% demonstrates continued momentum.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : PHR

The primary concerns for PHR are EPS Growth, Market Cap, Return on Equity. A P/E of 62.9x leaves little room for execution misses. Thin 1.9% margins leave little buffer for downturns.

Key Dynamics to Monitor

PHR carries more volatility with a beta of 0.88 — expect wider price swings.

PHR is growing revenue faster at 12.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRK scores higher overall (50/100 vs 44/100). PHR offers better value entry with a 72.6% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Phreesia Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Phreesia, Inc. provides integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company is headquartered in Raleigh, North Carolina.

Want to dig deeper into these stocks?